Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.78
-$0.11(-3.01%)
At close: 4:00 PM EST
$0.78
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.30 - $3.48
Previous CloseN/A
Volume8.73K
Average Volume (3M)101.31K
Market Cap
$1.14M
Enterprise Value$825.28K
Total Cash (Recent Filing)$3.11M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3838.80
Shares Outstanding3,959,792
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda-0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Capability ExpansionAcquiring Recipharm Israel creates a second manufacturing site and consolidates CDMO activities, structurally shifting the company toward fee-for-service revenue. Over months this should diversify income, provide operational scale for biologics and injectables, and reduce reliance on R&D-only funding cycles.
Improved Balance Sheet LeverageMaterial debt reduction and restored positive equity provide a stronger capital base and greater financial flexibility. Lower leverage reduces solvency risk and gives management more optionality to invest in CDMO scale-up or advance pipeline programs without immediate insolvency pressure.
Access To Capital And Non-dilutive FundingSuccessful private placement plus pursuit of grants demonstrates multi-channel funding ability. A mix of equity financings and active pursuit of non-dilutive grants supports the company’s runway and enables targeted investments in CDMO capabilities and lead immunology assets over the coming months.
Bears Say
Persistent Cash BurnSustained negative operating cash flow and free cash flow indicate the business continues to consume cash to fund operations. Over a multi-month horizon this necessitates repeated financing, constrains investment choices, and increases execution risk if capital markets tighten or grant timelines slip.
Loss-Making Acquired SubsidiaryThe acquired Recipharm Israel entity carries audited losses, a working-capital shortfall and a going-concern note. Integrating a loss-making CDMO can strain consolidated cash, require additional capital support, and complicate margin improvement timelines, weakening near-term financial durability.
Nasdaq Listing Compliance RiskA formal Nasdaq minimum bid price deficiency creates a structural listing risk that could impair liquidity and access to US capital markets if unresolved. Addressing it may force management to prioritize short-term remediation measures over long-term operational investments.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.30 and its highest was $3.48 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.14M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 60 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Jun 10, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,959,792 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -7.627%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
0.37% Other Institutional Investors
99.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---